Bartoli Francesco, Riboldi Ilaria, Bachi Bianca, Calabrese Angela, Moretti Federico, Crocamo Cristina, Carrà Giuseppe
Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, Italy.
Division of Psychiatry, University College London, Maple House 149, London W1T 7BN, UK.
J Clin Med. 2021 Mar 22;10(6):1303. doi: 10.3390/jcm10061303.
Although cannabis' major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders.
尽管大麻的主要精神活性成分Δ-9-四氢大麻酚（THC）与精神障碍的发病较早和预后较差都有关联，但大麻二酚（CBD）似乎具有不同的药理机制和潜在治疗特性。然而，到目前为止，尚无临床研究调查CBD用于治疗同时存在的精神障碍和大麻使用障碍，尽管其效用似乎有合理的生物学基础。因此，这项工作的目的是概述评估CBD对THC诱发的精神病症状、精神分裂症和大麻使用障碍疗效的现有临床研究。在PubMed、Cochrane图书馆和ClinicalTrials.gov中检索相关研究后，我们纳入了10项临床研究。现有证据表明，CBD可能减轻健康志愿者中由THC诱发的类精神病症状以及精神分裂症患者的阳性症状。此外，关于CBD治疗大麻使用障碍疗效的初步数据结果不一。正在进行的临床研究的证据将深入了解CBD在治疗精神障碍和大麻使用障碍方面的可能作用。
